Elranatamab
Trade name: Elrexfio
mAbapprovedMulti-specificOrphan Drug FDAFast Track FDABreakthrough Therapy FDA
Approved
Aug 14, 2023
Clinical trial activity
36 trials · 25 clinical orgs · 1 marketing orgs
Phase 1
11
Phase 2
26
Phase 3
5
Phase 4
1
Earliest trial started Nov 29, 2017 (NCT03269136)
Timeline
2020s
Indications
Approved for
Mechanism of action
CD3E activator
- BCMABINDING AGENT
BCMA binding agent
- T cell surface glycoprotein CD3BINDING AGENT
T cell surface glycoprotein CD3 binding agent
Directs cytotoxic T-cells to tumours
- Tumor necrosis factor receptor superfamily member 17BINDING AGENT
Tumor necrosis factor receptor superfamily member 17 binding agent
Directs cytotoxic T-cells to tumours
Approval history
- approvedPriority reviewAcceleratedFast trackBreakthroughAug 14, 2023
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Multi-specific
- Yes
Oral
No
Parenteral
Yes
Topical
No
Black box warning
Sources
- ChEMBLCHEMBL4297809 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06832865 | Phase 2 | Aug 1, 2026 | Harvard University, Pfizer, Sanofi |
| NCT07280013 | Phase 1 | Apr 30, 2026 | C4 Therapeutics, Inc. |
| NCT07247097 | Phase 2 | Apr 15, 2026 | Harvard University, Pfizer |
| NCT06988488 | Phase 1/Phase 2 (Phase 2) | Oct 7, 2025 | Bristol-Myers Squibb, Celgene |
| NCT06997081 | Phase 2 | Sep 16, 2025 | Pfizer, University of Miami |
| NCT06974786 | Phase 2 | Aug 8, 2025 | Colorado Blood Cancer Institute, Pfizer, SCRI Development Innovations |
| NCT06918002 | Phase 3 | Jul 9, 2025 | Intergroupe Francophone du Myelome, Pfizer |
| NCT06947083 | Phase 2 | May 7, 2025 | Pfizer, University of South Florida |
| NCT06931704 | Phase 2 | May 1, 2025 | University of Nantes |
| NCT06799026 | Phase 1 | Jan 31, 2025 | Harvard University, Pfizer |
| NCT06483100 | Phase 2 | Dec 31, 2024 | National Comprehensive Cancer Network, Pfizer, Washington University in St. Louis |
| NCT06711705 | Phase 2 | Dec 31, 2024 | University of California, San Diego |
| NCT06421675 | Phase 2 | Nov 30, 2024 | McMaster University, Pfizer |
| NCT06645678 | Phase 1/Phase 2 (Phase 2) | Oct 24, 2024 | Seoul National University |
| NCT06569147 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2024 | Harvard University |
| NCT06207799 | Phase 2 | Jul 17, 2024 | Pfizer, University of Texas at Houston |
| NCT06138275 | Phase 2 | Apr 24, 2024 | Harvard University, Pfizer |
| NCT06215118 | Phase 1 | Feb 20, 2024 | Bristol-Myers Squibb, Pfizer |
| NCT06183489 | Phase 2 | Jan 31, 2024 | European Myeloma Network, Pfizer |
| NCT06015542 | Phase 2 | Jan 1, 2024 | Odense University Hospital, Pfizer, University of Southern Denmark |
Showing 20 of 36 trials
Page 1 / 2
Organizations
Research & Development (25)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 28 | 15 | 5 | 2017 |
| Harvard University | Academic/Hospital | 5 | 5 | 2 | 2024 |
| Bristol-Myers Squibb | For profit | 2 | 0 | 2 | 2024 |
| C4 Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2026 |
| Celgene | For profit | 1 | 1 | 1 | 2025 |
| Colorado Blood Cancer Institute | Academic/Hospital | 1 | 0 | 1 | 2025 |
| European Myeloma Network | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Genentech | For profit | 1 | 1 | 1 | 2023 |
| Intergroupe Francophone du Myelome | Academic/Hospital | 1 | 1 | 1 | 2025 |
| McMaster University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| National Comprehensive Cancer Network | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Odense University Hospital | Academic/Hospital | 1 | 0 | 1 | 2024 |
| PETHEMA Foundation | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Roche | For profit | 1 | 0 | 1 | 2023 |
| Sanofi | For profit | 1 | 0 | 1 | 2026 |
| SCRI Development Innovations | For profit | 1 | 1 | 1 | 2025 |
| Seoul National University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of California, San Diego | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Miami | Academic/Hospital | 1 | 1 | 1 | 2025 |
| University of Nantes | Academic/Hospital | 1 | 1 | 1 | 2025 |
25 organizations
Page 1 / 2